nature portfolio

corresponding author(s):	Linkai Huang, Shilin Tian
Last updated by author(s)	: Jan 11, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

⋖.	トつ	ıτı	ct	- 1	CS
J	ιa	L	I O I		LJ

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\times		A description of all covariates tested
\times		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
	\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	'	Our web collection on statistics for biologists contains articles on many of the points above

our web conection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No software was used in data collection.

Data analysis

Flow cytometry analysis: Kaluza (v2.1.3).

Initial assembly: Hifiasm package (v0.13-r308), Pruge_haplotig (v1.1.0), Bionano Solve (v3.5.1).

Pseudochromosome construction: BWA (v0.7.8), ALLHIC package (v0.9.8).

Genome assessment: BUSCO (v4.1.2), CEGMA (v2.5), BWA (v0.7.8), Merqury (v1.3), LTR_retriever (v2.8).

Annotation of repetitive sequences: RepeatMasker (v4.0.5), LTR_FINDER (v1.0.7), Piler (v3.3.0), RepeatScout (v1.0.5), RepeatModeler (v1.0.8), MUSCLE (v3.8.31).

Annotation of gene structure: TblastN (v2.2.26), Solar (v0.9.6), GeneWise (v2.4.1), TopHat (v2.0.13), Cufflinks (v2.1.1), Trinity (v2.1.1), PASA, Augustus (v3.2.3), GENSCAN (v1.0), GlimmerHMM (v3.0.1), EVidenceModeler (v1.1.1), SNAP (v2013.11.29), geneid (v1.4).

Functional annotation of protein-coding genes: InterProScan (v4.8), HMMER (v3.1), InterPro (v32.0), Pfam (v27.0).

Comparative genomic analysis across species: BLASTP (v2.2.26), Orthofinder (v2.3.1), MUSCLE (v3.8.31), RAXML (v8.0.19), MCMCTree program (v4.5).

Pan-genome construction: Orthofinder (v2.3.1).

SV identification: MUMmer (v4.0.0), SyRI (v1.6.3), vg (v1.25.0).

Validation of structural variations: SyRI (v1.6.3), Assmeblytics, smartie-sv, vg (v1.25.0), HISAT2 (v2.2.1).

TF family identification and analysis: Fimo (v5.3.2), iTAK tool (v1.7 a).

PAV-GWAS: GEMMA (v0.94.1), LightGBM.

RNA-seq: FastQC (v0.11.9), Kallisto (v0.46.2), DESeq2 (1.26.0).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

randomly selected and stored in cryogenic vials.

Blinding

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The raw sequencing data and transcriptome data of PI186338, PI250656, PI343841, PI521612, PI526529, PI527388, PI537069, PI583800, PI587025, and Tifleaf3 have been deposited in the NCBI Sequence Read Archive under BioProject accession numbers PRJNA749489, PRJNA689619, and PRJNA756390. The assemblies of ten pearl millet have been deposited in NCBI GenBank under the accession numbers JAMZRY000000000 (PI343841), JAMOAQ000000000 (PI250656), JAMKQL000000000 (PI186338), JAMKQK000000000 (PI527388), JAJHQD000000000 (PI587025), JAJFIR000000000 (PI537069), JAINUP000000000 (Tifleaf3), JAINUP0000000000 (PI583800), JAINUN0000000000 (PI526529), and JAINUM000000000 (PI521612). These assemblies are also available at a website (http://117.78.45.2:91/download). The raw genome assembly data are available under accession number PRJNA749489. The transcriptomic data are available under accession numbers PRJNA749489, PRJNA689619, and PRJNA756390. The public RNA-seq data used was downloaded from NCBI and the bioproject accession numbers is PRJNA520822. The public re-sequence data used was downloaded from NCBI and the accession number is SRP063925. Source data are provided with this paper.

anna hahan		
Human rese	arch parti	cipants
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.
Reporting on sex	and gender	not applicable
Population chara	cteristics	not applicable
Recruitment		not applicable
Ethics oversight		not applicable
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.
Field-spe	ecific re	porting
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	E	Behavioural & social sciences
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces sti	udy design
All studies must dis	close on these	points even when the disclosure is negative.
Sample size	pan-genome ba a published stu as the reference	ple; Hi-C: 2 samples; Pacbio HiFi: 10 samples; Illumina: 228 samples. no sample size calculation was performed. We built the ased on 11 representative accessions where 10 samples are de-novo assembled in our study and one sample downloaded from dy. We used Bionano and Hi-C sequencing for PI537069 accession, aiming to obtain a high-quality assemble that could be used be genome for the SV discoveries in the downstream analysis. For the 228 samples of Illumina sequencing, we did bulk RNA-seq ing leaf and root tissues and eight time points underlying heat stressful conditions (Supplementary Table 1: Overview of RNA-
Data exclusions	For PAV-GWAS data.	we excluded samples without phenotype data. For temperature adaptation analyses, we excluded samples without latitude
Replication	_	al and three technical replicates for Dual-luciferase assays. Two biological and one technical replicates for Tobacco leaf assays. One biological and technical replicate for PCR validation. Three biological replicates for physiological analysis. Two ow cytometry.
Randomization	Plants were rar	ndomly allocated in the greenhouse. tobacco leaves were randomly collected from individuals with same growth stages. For

evaluation of contig connections, we randomly picked several to present in the Extended Fig. 1e. To further validate the SVs, we performed a PCR genotyping to validate three SVs randomly picked from the SV pool. For RNA-seq, the leaves or roots of 16 seedlings with consistent growth were randomly selected and stored in cryogenic vials. For Physiological indicators, the leaves of plants with consistent growth were

The experiments were conducted blindly. All genotypes were only labeled by numbers when planting, so the investigators did not know the

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental s	ystems Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeol	logy MRI-based neuroimaging
Animals and other organism	ns
Clinical data	
Dual use research of concer	'n
Flow Cytometry	
Plots	
Confirm that:	L
	ker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly vis	ible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots wi	ith outliers or pseudocolor plots.
A numerical value for number	er of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	About 20mg leaves, add 1ml MGB, add 500µl lysis buffer, 25µl 50µg/ml Pl and 25µl 50µg/ml RNase, mix and shade before use.
Instrument	Beckman CytoFLEX.
Software	CytExpert (version:2.3.0.84).
Cell population abundance	CytoFLEX flow cytometer automatically collects cells and counts the number.
Gating strategy	Use FSC-A/SSC-A to select cells, use PE-A/PE-H to exclude cell debris, and select the location of the positive result of PI staining.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.